Neurocrine Biosciences, Inc. (NBIX)
128.13
-1.51
(-1.16%)
USD |
NASDAQ |
Mar 06, 16:00
128.18
+0.05
(+0.04%)
After-Hours: 20:00
Neurocrine Biosciences Cash from Investing (TTM) : -264.40M for Dec. 31, 2025
Cash from Investing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (TTM) Benchmarks
| Glaukos Corp. | -77.61M |
| Edgewise Therapeutics, Inc. | -32.79M |
| Nuvalent, Inc. | -124.08M |
| Marker Therapeutics, Inc. | 0.00 |
| CapsoVision, Inc. | -- |